Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
Holding MDWD?
Track your performance easily
MDWD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.45 - $24.00
Previous Close$17.57
Volume47.32K
Average Volume (3M)176.13K
Market Cap
$189.52M
Enterprise Value$154.16M
Total Cash (Recent Filing)$41.71M
Total Debt (Recent Filing)$6.35M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 12, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding10,790,000
10 Day Avg. Volume38,664
30 Day Avg. Volume176,133
Standard Deviation0.17
R-Squared0.06
Alpha0.00144
Financial Highlights & Ratios
Price to Book (P/B)6.32
Price to Sales (P/S)10.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.72
Enterprise Value/Gross Profit43.09
Enterprise Value/Ebitda-23.69
Forecast
1Y Price Target
$29.75Price Target Upside69.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Mediwound News
PremiumCompany Announcements
MediWound’s NexoBrid Gains FDA Pediatric Approval
PremiumCompany Announcements
MediWound’s Financial Success and Growth
PremiumCompany Announcements
MediWound’s Strategic Growth and Solid Q2 2024 Performance
PremiumCompany Announcements
MediWound’s NexoBrid Triumphs in Burn Care StudyBulls Say, Bears Say
Bulls Say
Expansion Of MarketPotential marketing approval for pediatric use of NexoBrid could notably widen its market, promising increased sales prospects.
Manufacturing Scale-UpMediWound's strategic investment in a new manufacturing facility is poised to substantially boost production capacity, readying the company for heightened product demand.
Revenue GrowthAnalyst expects robust revenue growth for NexoBrid, projecting a surge of over 40% in 2024 following its successful launch in significant markets.
Bears Say
Clinical TrialThe company has had to adjust its clinical trial strategy by reducing the number of participants, potentially impacting the robustness of trial outcomes.
EarningsTotal revenue in Q3 was significantly lower than the previous year, mainly as a result of missing one-time income that had boosted past figures.
Revenue DeclineA noticeable decrease in quarterly revenue has been observed, signaling potential challenges in the company's ability to generate consistent income streams.
---
Ownership Overview
0.00%
Insiders
0.35% Mutual Funds
17.89% Other Institutional Investors
81.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $7.45 and its highest was $24.00 in the past 12 months.
What is Mediwound’s market cap?
Currently, no data Available
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Aug 14, 2024. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.26.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -$0.45.
How many shares outstanding does Mediwound have?
Mediwound has 10,786,423 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went down -4.064%.
Which hedge fund is a major shareholder of Mediwound?
Among the largest hedge funds holding Mediwound’s share is ARK Investment Management LLC. It holds Mediwound’s shares valued at N/A.
---
Mediwound Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.75 (69.32% Upside)
$29.75 (69.32% Upside)
Hedge Fund Trend
Decreased
By 2.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 12.0%
Last 30 Days ▼ 12.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.20%
12-Months-Change
Fundamentals
Return on Equity
-75.66%
Trailing 12-Months
Asset Growth
-10.98%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
---
MDWD Earnings Call
Q2 2024
0:00 / 0:00
---
MDWD Stock 12 Month Forecast
Average Price Target
$29.75
▲(69.32% Upside)
Technical Analysis
Best Analysts Covering MDWD
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+50.25%
reiterated a buy rating last month
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +50.25% per trade.
---